Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data MediWound Ltd. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1.56
2.5
3.4
31.8
21.8
23.8
26.5
18.7
20.2
17
Cost of revenue
2.16
1.58
2.09
11.8
14.2
15
13.3
15.1
17.6
13.7
Gross profit
-0.6
0.92
1.31
19.9
7.55
8.77
13.2
3.58
2.63
3.25
Research and development
7.07
5.46
4.07
4.97
7.7
10.3
10.2
7.47
8.88
14.3
Selling, general and administrative
4.08
3.78
3.8
5.24
5.46
6.35
6.92
6.77
8.2
8.45
Operating income
-20.2
-13.7
-3.96
4.49
-8.84
-11.2
-8.35
-15.3
-19.4
-25.3
Interest expense
0.9
1.25
2.12
2.98
1.28
2.31
11.6
1.89
12.8
2.46
Interest income
2.17
0.41
0.41
0.56
0.84
0.01
0.46
10.7
2.05
4.02
Pre-tax income
2.07
-9.28
-13.5
-19.5
-6.53
-30.2
-23.7
Income tax
0
0
0.03
0.08
0.19
0.06
0.17
Income from continuing operations
-18.9
-14.5
-5.67
2.07
-9.28
-13.6
-19.6
-6.72
-30.2
-23.9
Net income
-18.9
-22.1
-1.06
4.96
-9.2
-13.6
-19.6
-6.72
-30.2
-23.9
EBITDA
-19.7
-13.2
-3.49
5.01
-8.45
-10.7
-7.92
-14.6
-18.8
-24.7
EPS, basic
-6.02
-6.65
-0.28
1.26
-2.38
-3.48
-3.93
-0.75
-3.03
-2.10
EPS, diluted
-6.02
-6.65
-0.28
1.26
-2.38
-3.48
-3.93
-0.75
-3.03
-2.10
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
28.9
36.1
6.72
7.24
17.4
11
33.9
11.9
9.16
4.8
Inventory
0.84
1.89
1.68
1.61
1.38
1.2
1.96
2.85
2.69
4.09
Total current assets
33.6
41.5
32.7
35.6
26.2
15
45.8
49.7
52.2
60
Property, plant and equipment
1.28
1.92
2.02
2.3
2.63
2.48
2.37
9.23
14.1
18.6
Lease right-of-use assets
2.23
1.88
1.55
1.22
6.7
6.66
7.15
Intangible assets
0.77
0.64
0.5
0.43
0.36
0.3
0.23
0.17
0.1
0.03
Total assets
35.8
44.1
35.3
40.6
31.1
19.7
50
66.5
73.5
86.3
Accounts payable
5.53
5.28
7.65
Total current liabilities
5.38
5.43
4.9
10.4
8.27
10.7
12.1
18.1
26.5
25.7
Lease liabilities
0
2.01
1.74
1.39
0.85
6.35
6.51
8.15
Total liabilities
28
34.8
26.3
25.4
23.8
24.3
39.1
34.9
42.3
42.6
Paid-in capital
115
139
140
141
142
144
179
206
236
272
Retained earnings
-107
-129
-131
-126
-135
-149
-168
-175
-205
-229
Total equity
7.77
9.37
8.97
15.2
7.27
-4.58
10.9
31.6
31.2
43.6
Total liabilities and equity
35.8
44.1
35.3
40.6
31.1
19.7
50
66.5
73.5
86.3
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-18.9
-22.1
-1.06
4.96
-9.2
-13.6
-19.6
-6.72
-30.2
-23.9
Depreciation and amortization
0.48
0.46
0.47
0.51
0.39
0.56
0.43
0.67
0.63
0.59
Cash from operations
-16.4
-16.5
-12.2
8.29
-6.9
-8.92
-11.9
-10.5
-13.6
-16.1
Capital expenditures
-0.67
-1.05
-0.52
-0.79
-0.92
-0.49
-0.56
-6.46
-6.27
-5.51
Cash from investing
1.82
0.44
-17
-6.9
17.4
3.55
-0.48
-34.3
-8.4
-18
Stock issued
22.7
0
0
38.4
Cash from financing
0.91
23
0.05
-1.05
35.8
22.9
19.4
29.6
Exchange rate effect
0.09
0.23
-0.21
0.14
0.27
0.09
-0.55
-0.16
-0.08
0.1
Net change in cash
-13.6
8.77
-29.4
3.36
10.3
-6.33
22.8
-22
-2.71
-4.36
Free cash flow
-17.1
-17.5
-12.7
7.5
-7.82
-9.41
-12.4
-16.9
-19.9
-21.6
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $13.84 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
19.2%
Gross profit / revenue.
Operating margin
-149.0%
Operating income / revenue.
EBITDA margin
-145.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-139.8%
Pre-tax income / revenue.
Net margin
-140.8%
Net income / revenue.
FCF margin
-127.5%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-95.1%
Cash from operations / revenue.
Return on assets (ROA)
-29.9%
Net income / average total assets.
R&D / revenue
84.4%
Research and development expense / revenue.
SG&A / revenue
49.8%
Selling, general and administrative expense / revenue.
Capex / revenue
32.5%
Capital expenditures / revenue.
D&A / revenue
3.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-16.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-13.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-4.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
23.5%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-37.2%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
-15.5%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
17.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
19.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
22.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.33x
Current assets / current liabilities.
Quick ratio
0.19x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.19x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
49.4%
Total liabilities / total assets.
Interest coverage
-10.3x
Operating income / interest expense.
Working capital
$34.3M
Current assets - current liabilities.
Goodwill and intangibles / assets
0.0%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.21x
Revenue / average total assets.
Fixed asset turnover
1.03x
Revenue / average property, plant and equipment.
Inventory turnover
4.04x
Cost of revenue / average inventory.
Days inventory
90 days
365 x average inventory / cost of revenue.
Days payables
172 days
365 x average accounts payable / cost of revenue.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$2.10
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$2.10
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$178.7M
Share price x shares outstanding.
Enterprise value
$173.9M
Market cap + total debt - cash - short-term investments.
P/S
10.5x
Market cap / revenue.
EV/Sales
10.3x
Enterprise value / revenue.
FCF yield
-12.1%
Free cash flow / market cap.
Earnings yield
-13.4%
Net income / market cap (the inverse of P/E).
What was MediWound Ltd.'s revenue in fiscal 2025?
MediWound Ltd. reported revenue of $17.0M for fiscal 2025, 16.1% lower than the year before.
Was MediWound Ltd. profitable in fiscal 2025?
No. It reported a net loss of $23.9M.
How much free cash flow did MediWound Ltd. generate in fiscal 2025?
Cash from operations of $16.1M minus capital expenditures of $5.5M left free cash flow of -$21.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.